{"id":"https://openalex.org/W4389958002","doi":"https://doi.org/10.1161/circ.148.suppl_1.15201","title":"Abstract 15201: Obicetrapib as an Adjunct to Stable Statin Therapy Significantly Lowers LDL-C, Non-HDL-C, and Apolipoprotein B in Japanese Patients: Results From the Japan Phase 2 Study","display_name":"Abstract 15201: Obicetrapib as an Adjunct to Stable Statin Therapy Significantly Lowers LDL-C, Non-HDL-C, and Apolipoprotein B in Japanese Patients: Results From the Japan Phase 2 Study","publication_year":2023,"publication_date":"2023-11-07","ids":{"openalex":"https://openalex.org/W4389958002","doi":"https://doi.org/10.1161/circ.148.suppl_1.15201"},"language":"en","primary_location":{"id":"doi:10.1161/circ.148.suppl_1.15201","doi":"https://doi.org/10.1161/circ.148.suppl_1.15201","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1161/circ.148.suppl_1.15201","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028921297","display_name":"Mariko Harada\u2010Shiba","orcid":"https://orcid.org/0000-0002-7600-2059","observed_orcids":["https://orcid.org/0000-0002-7600-2059"]},"institutions":[{"id":"https://openalex.org/I205143321","display_name":"Osaka Medical and Pharmaceutical University","ror":"https://ror.org/01y2kdt21","country_code":"JP","type":"education","lineage":["https://openalex.org/I205143321"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mariko Harada-Shiba","raw_affiliation_strings":["Osaka Med and Pharmaceutical Un, Takatsuki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka Med and Pharmaceutical Un, Takatsuki, Japan","institution_ids":["https://openalex.org/I205143321"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015384592","display_name":"Douglas F. Kling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Douglas Kling","raw_affiliation_strings":["NewAmsterdam Pharma, Naarden, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewAmsterdam Pharma, Naarden, Netherlands","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077848934","display_name":"John J.P. Kastelein","orcid":"https://orcid.org/0000-0003-2018-4532","observed_orcids":["https://orcid.org/0000-0003-2018-4532"]},"institutions":[{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"John J Kastelein","raw_affiliation_strings":["Academic Med Cntr, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Academic Med Cntr, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I2802928900"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079365240","display_name":"Marc Ditmarsch","orcid":"https://orcid.org/0000-0002-2970-1893","observed_orcids":["https://orcid.org/0000-0002-2970-1893"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Marc Ditmarsch","raw_affiliation_strings":["NewAmsterdam Pharma, Naarden, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewAmsterdam Pharma, Naarden, Netherlands","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093533626","display_name":"Erin Wuerdeman","orcid":"https://orcid.org/0009-0004-2896-2452","observed_orcids":["https://orcid.org/0009-0004-2896-2452"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Erin Wuerdeman","raw_affiliation_strings":["NewAmsterdam Pharma, Naarden, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewAmsterdam Pharma, Naarden, Netherlands","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101407871","display_name":"Andrew Hsieh","orcid":"https://orcid.org/0000-0001-6671-6878","observed_orcids":["https://orcid.org/0000-0001-6671-6878","https://orcid.org/0009-0004-2371-6869"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Andrew Hsieh","raw_affiliation_strings":["NewAmsterdam Pharma, Naarden, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewAmsterdam Pharma, Naarden, Netherlands","institution_ids":["https://openalex.org/I4405272097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055849986","display_name":"Stephen James Nicholls","orcid":"https://orcid.org/0000-0002-9668-4368","observed_orcids":["https://orcid.org/0000-0002-9668-4368"]},"institutions":[{"id":"https://openalex.org/I2801350665","display_name":"Monash Medical Centre","ror":"https://ror.org/036s9kg65","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2801350665","https://openalex.org/I4210121067"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Stephen Nicholls","raw_affiliation_strings":["Monash Med Cntr, Clayton, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash Med Cntr, Clayton, Australia","institution_ids":["https://openalex.org/I2801350665"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101777206","display_name":"Michael H. Davidson","orcid":"https://orcid.org/0000-0001-9342-1274","observed_orcids":["https://orcid.org/0000-0001-9342-1274"]},"institutions":[{"id":"https://openalex.org/I4405272097","display_name":"NewAmsterdam Pharma (Netherlands)","ror":"https://ror.org/03jdnwh76","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405272097"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Michael Davidson","raw_affiliation_strings":["NewAmsterdam Pharma, Naarden, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NewAmsterdam Pharma, Naarden, Netherlands","institution_ids":["https://openalex.org/I4405272097"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"148","issue":"Suppl_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/obicetrapib","display_name":"obicetrapib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cetp-inhibitors","display_name":"CETP inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.828000009059906},{"id":"https://openalex.org/keywords/non-hdl-cholesterol","display_name":"non-HDL cholesterol","score":0.890999972820282},{"id":"https://openalex.org/keywords/apolipoprotein-b","display_name":"apolipoprotein B","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hdl-cholesterol","display_name":"HDL cholesterol","score":0.9810000061988831},{"id":"https://openalex.org/keywords/statin-therapy","display_name":"statin therapy","score":0.6990000009536743},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.8019999861717224},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.6930000185966492},{"id":"https://openalex.org/keywords/asian-populations","display_name":"Asian populations","score":0.7390000224113464},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.6679999828338623},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5339999794960022},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.5189999938011169},{"id":"https://openalex.org/keywords/hypertriglyceridemia","display_name":"hypertriglyceridemia","score":0.7409999966621399},{"id":"https://openalex.org/keywords/atherosclerotic-cardiovascular-disease","display_name":"atherosclerotic cardiovascular disease","score":0.6150000095367432}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9192661046981812},{"id":"https://openalex.org/C2778657065","wikidata":"https://www.wikidata.org/wiki/Q417997","display_name":"Ezetimibe","level":3,"score":0.8289711475372314},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6746540665626526},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6670019626617432},{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.6196070313453674},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.6104487180709839},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5390896201133728},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5049257874488831},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.46506789326667786},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3712904453277588},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.3617418706417084},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.33405163884162903},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1161/circ.148.suppl_1.15201","doi":"https://doi.org/10.1161/circ.148.suppl_1.15201","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1161/circ.148.suppl_1.15201","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393647064","https://openalex.org/W4415791698","https://openalex.org/W4410850409","https://openalex.org/W4379259785","https://openalex.org/W4292242012","https://openalex.org/W4415790603","https://openalex.org/W4297452823","https://openalex.org/W7128048321","https://openalex.org/W4413075870","https://openalex.org/W4403122121"],"abstract_inverted_index":{"Background:":[0],"Obicetrapib":[1,183,218],"is":[2,43,92],"a":[3,44,93],"selective":[4],"CETP":[5],"inhibitor":[6],"that":[7],"has":[8],"been":[9],"shown":[10],"to":[11,67,75,138,164,229,251],"reduce":[12],"LDL-C,":[13,267],"non-HDL-C,":[14,174],"lipoprotein":[15],"particles,":[16],"and":[17,23,74,113,123,175,198,212,259,269,281],"apolipoproteins":[18],"when":[19,51],"used":[20,52],"as":[21],"monotherapy,":[22],"in":[24,38,53,71,104,160,172,237,245,263,266,271],"combination":[25,54],"with":[26,49,55,106,114,222],"ezetimibe,":[27],"on":[28],"background":[29,132],"high-intensity":[30],"statins.":[31],"Previous":[32],"studies":[33],"of":[34,46,81,95,187,200,208,277],"obicetrapib":[35,50,82,139,143,147,254,278],"were":[36,135,180,232,279],"conducted":[37],"predominantly":[39],"Caucasian":[40],"participants.":[41],"There":[42,231],"lack":[45],"clinical":[47,72],"experience":[48,73],"stable":[56,130],"statin":[57,131],"therapy":[58],"among":[59],"Asian":[60,85,273],"population.":[61,86,274],"Objectives:":[62],"This":[63],"study":[64,91],"was":[65,157,219],"designed":[66],"fill":[68],"the":[69,77,84,107,272],"gap":[70],"characterize":[76],"safety,":[78],"efficacy":[79],"profile":[80],"within":[83],"Methods:":[87],"The":[88,154],"Phase":[89],"2":[90],"trial":[94],"Japanese":[96],"participants":[97],"who":[98],"had":[99],"not":[100],"achieved":[101],"treatment":[102,224,247],"goal":[103],"accordance":[105],"2022":[108],"Japan":[109],"Atherosclerosis":[110],"Society":[111],"Guidelines":[112],"LDL-C":[115,161,189],">70":[116],"mg/dL":[117,122],"or":[118,151,242],"non-HDL-C":[119,195,270],">":[120],"100":[121],"TG":[124],"<":[125],"400":[126],"mg/dL,":[127],"while":[128],"receiving":[129],"therapy.":[133],"Participants":[134],"randomized":[136],"1:1:1:1":[137],"2.5":[140,255],"mg":[141,145,149,261],"(n=25),":[142,146],"5":[144,257],"10":[148,260],"(n=26),":[150],"placebo":[152],"(n=26).":[153],"primary":[155],"endpoint":[156],"percent":[158],"change":[159,207],"from":[162],"baseline":[163],"week":[165],"8.":[166],"Key":[167],"secondary":[168],"endpoints":[169],"included":[170],"changes":[171,236],"ApoB,":[173,268],"HDL-C.":[176],"Standard":[177],"safety":[178],"assessments":[179],"conducted.":[181],"Results:":[182],"produced":[184],"significant":[185,235,264],"lowering":[186],"median":[188,206],"(45.8%,":[190],"P<0.0001),":[191,194],"ApoB":[192],"(29.7%,":[193],"(37.0%,":[196],"P<0.0001)":[197],"raising":[199],"HDL-C":[201],"(158.9%,":[202],"P<0.0001).":[203],"Placebo":[204],"demonstrated":[205],"-0.9%,":[209],"-0.4%,":[210],"-0.4%":[211],"+5.2%":[213],"for":[214],"these":[215],"parameters":[216],"respectively.":[217],"well":[220,282],"tolerated":[221],"similar":[223],"emergent":[225],"adverse":[226],"events":[227],"compared":[228],"placebo.":[230],"no":[233],"clinically":[234],"laboratory":[238],"parameters,":[239],"vital":[240],"signs,":[241],"physical":[243],"examinations":[244],"any":[246],"group.":[248],"Conclusions:":[249],"Similar":[250],"previous":[252],"studies,":[253],"mg,":[256,258],"resulted":[262],"reductions":[265],"All":[275],"doses":[276],"safe":[280],"tolerated.":[283]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2023-12-20T00:00:00"}